Transcenta Therapeutics and WuXi Biologics announced a licensing and commercialization partnership aimed at scaling Transcenta’s HiCB platform and ExcelPro cell culture media. The collaboration includes an upfront payment of $1.5 million and milestone payments tied to specified conditions. The agreement positions WuXi Biologics as Transcenta’s strategic partner for CMC development across molecules in Transcenta’s pipeline. The companies say HiCB combines intensified continuous perfusion upstream processing with hybrid continuous downstream purification to improve productivity and reduce cost of goods. The deal reflects ongoing industry demand for process innovation that can shorten development timelines and improve manufacturing efficiency for complex biologics.